ZYUS Life Sciences, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public, Subsidiary
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.zyus.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Unique Treatment of Oncology Pain in Advanced Cancer
Phase 2
Recruiting
- Conditions
- Cancer Pain
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- ZYUS Life Sciences Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06533657
- Locations
- 🇨🇦
Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation
Phase 1
Completed
- Conditions
- HealthyOsteoarthritis
- Interventions
- Drug: Trichomylin for MADDrug: Placebo for SADDrug: Placebo for MADDrug: Trichomylin for SAD
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- ZYUS Life Sciences Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04867057
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
News
No news found